Untitled
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
DRAG
As Seen on People
As Seen on BOTCHED
As Seen on ABC
As Seen on Haute Beauty
As Seen on New Beauty
As Seen on The Doctors

The Renuvion APR Handpiece is intended for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. The Renuvion APR Handpiece is intended for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. The Renuvion APR Handpiece is indicated for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental region. The Renuvion APR Handpiece is intended for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. The Renuvion APR Handpiece is intended to be used with compatible electrosurgical generators owned by Apyx Medical. Not all indications are approved in all markets; check with your local sales representative for further information.

As with any aesthetic procedure, individual results may vary. As with all energy devices there are inherent risks associated with its use. Risk associated with the use of the Renuvion APR may include: helium embolism into the surgical site due to inadvertent introduction into the venous or arterial blood supply system, unintended burns (deep or superficial), pneumothorax, temporary or permanent nerve injury, ischemia, fibrosis, infection, pain, discomfort, gas buildup resulting in temporary and transient crepitus or pain, bleeding, hematoma, seroma, subcutaneous induration, pigmentation changes, increased healing time, scarring, asymmetry and/ or unacceptable cosmetic result. Please see the instructions for use for more detailed information.

Reference:
1. 4 out of 5 surgeons agree Renuvion is the #1 trusted body contouring technology. Results based on a 2024 Renuvion Physician survey conducted by Wakefield Research. Data on File.

back to top